The global dry eye treatment devices market size reached USD 425.51 million in 2023 and is expected to hit around USD 888.48 million by 2033 with a CAGR of 7.64% from 2024 to 2033.
The U.S. dry eye treatment devices market size was valued at USD 116.16 million in 2023 and is anticipated to reach around USD 242.56 million by 2033, poised to grow at a CAGR of 7.66% from 2024 to 2033.
To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics
North America emerged as a dominant force in the global dry eye treatment devices market in 2023, driven by significant prevalence and increasing awareness of dry eye disease. In January 2022, the eyes on eyecare team conducted a survey involving 540 eyecare professionals across North America, including 450 practicing optometrists. With the introduction of newer, costlier therapies, a heightened societal and personal economic burden of DED is anticipated. Contributing factors include the ongoing global pandemic and an aging population. Over-the-counter topical treatments remain popular. Prescription-based treatments, such as topical steroids, have seen a particularly significant increase, highlighting the evolving landscape of DED management in North America.
DED remains underdiagnosed despite its significant public health impact, suggesting a considerable undiagnosed burden of the disease. The vast geographical expanse of the USA, characterized by diverse climates, underscores the influence of climatic factors on DED risk, necessitating careful consideration of prevalence and incidence estimations. The prevalence of DED is on the rise, with an estimated 35 million affected individuals in the USA alone. In the United States, a meta-analysis estimated a pooled prevalence of DED at 8.1%, with personal costs often elevated due to limited health insurance coverage for treatments like ocular lubricants and higher drug costs.
The dry eye treatment devices market is experiencing significant growth driven by advancements in technology and increasing awareness about the condition. Dry eye disease (DED) affects a substantial portion of the population, with prevalence rates soaring as high as 95% among patients with blocked meibomian glands. This condition affects not only the elderly but also a considerable number of individuals across different age groups, with environmental factors such as low humidity, wind exposure, allergens, and smoke significantly exacerbating the symptoms.
Scientific evidence supports the efficacy of dry eye treatment devices in diagnosing the type and severity of the disease, particularly in evaporative dry eye disease cases. These devices offer a more comprehensive and long-term management solution compared to traditional treatments. In addition to addressing the symptoms of dry eye, these devices provide patients with comfortable vision, improving their overall quality of life. Notably, patients using topical antiglaucoma medications are particularly susceptible to dry eye, further driving the demand for innovative treatment options.
The market is witnessing a shift away from conventional eye drop formulations, which often contain preservatives like benzalkonium chloride that can induce ocular surface damage. The dry eye treatment devices market presents lucrative opportunities for manufacturers and investors alike, driven by the pressing need for effective, long-term solutions to this prevalent and often debilitating eye condition. Key players strive to dominate the market via collaborations, mergers, acquisitions, adoption of advanced technologies, and product launches.
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 7.64% |
| Global Market Size in 2023 | USD 425.51 Million |
| Global Market Size by 2033 | USD 888.48 Million |
| U.S. Market Size in 2023 | USD 116.16 Million |
| U.S. Market Size by 2033 | USD 242.56 Million |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Technology and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers
Addressing meibomian gland dysfunction and corneal damage through innovative solutions
The growth of the dry eye treatment devices market is primarily driven by the need to address discomfort stemming from blockages in the meibomian glands, which produce a protective oily layer for tears. These blockages lead to thickened meibum and clogged glands, exacerbating dry eye symptoms. Daily lubrication and warm compression at home, along with periodic deep cleaning of the glands, are essential for managing dry eye disease.
Dry eye treatment devices play a crucial role by massaging the meibomian glands and releasing clogged oils through heat application. Additionally, for patients with moderate-to-severe dry eye, lasting damage to the cornea may occur, necessitating the use of specialty contact lenses like scleral lenses to repair the corneal surface. These advancements in treatment options meet the increasing demand for comprehensive relief among individuals suffering from dry eye conditions.
Prevalence among high-risk populations
The rising prevalence of dry eye disease presents a significant driver for the growth of the dry eye treatment devices market, particularly among high-risk populations such as farmers and laborers. Individuals engaged in labor-intensive occupations are forced to endure prolonged exposure to adverse environmental conditions, including heat, sunlight, dust, wind, and chemical agents like fertilizers and insecticides. Despite facing heightened risk factors, this demographic often lacks access to protective equipment due to economic constraints and limited awareness.
The prevalence of dry eye among diabetic patients is alarmingly high, with a 67% prevalence rate. Among type 2 diabetic patients, 54.3% suffer from dry eye syndrome, further underscoring the pressing need for effective treatment solutions. This demographic represents a significant segment of the dry eye treatment devices market, highlighting the imperative for tailored interventions to address the unique needs of diabetic individuals and mitigate the impact of dry eye on their quality of life. Excessive environmental exposure contributes to this heightened risk, necessitating urgent awareness campaigns to promote the adoption of protective measures during work. While these initiatives may not entirely prevent dry eye incidence, they delay its onset and mitigate its severity.
Restraint
Limitations of the intranasal tear neurostimulator devices
Despite its potential benefits in treating dry eye, the adoption of the intranasal tear neurostimulator (ITN) device is hindered by several factors. The device is associated with common side effects, including nasal discomfort, burning, pain, nosebleeds, transient electrical discomfort, nasal congestion, facial pain, and headaches. Furthermore, its usage is contraindicated in patients with cardiac pacemakers, implanted or wearable defibrillators, or other implanted metallic or electronic devices in the head or neck, as well as those with hypersensitivity to the hydrogel coating the device probes or chronic nosebleeds.
The limitations associated with treatment options significantly narrow the eligible patient population for the device's use. The cost of the ITN device presents a significant barrier to widespread adoption. Priced at approximately $1000 with an additional monthly expense of approximately $50 for disposable tips, the device and its consumables are not covered by most insurance plans. This financial burden limits access to the device for many patients, thereby restraining the growth of the dry eye treatment devices market.
Regulatory hurdles
The medical devices are subjected to a series of regulatory tests and approvals prior to widespread human use. Authorities like the U.S. FDA and EMA thoroughly ensure the safety and efficacy of dry eye treatment devices before providing them with marketing approvals. The stringency maintained by pharma and biotechnological companies during the regulatory compliance procedure often creates additional financial and time-related issues. These may also contribute to the overall cost of the final product, significantly restraining the growth of the dry eye treatment devices market.
Opportunities
Tailored device options and personalization
In the dry eye treatment devices market landscape, a range of device options exist, each tailored to address specific indications. For instance, lacrimal intranasal neurostimulation proves beneficial for patients with aqueous tear deficiency, while scleral lenses offer advantages for those with irregular corneal surfaces, neurotrophic disease, or graft-versus-host disease. This individualized approach presents a significant opportunity in the market, particularly for patients unresponsive to conventional therapeutic options. By offering tailored device solutions, manufacturers can meet the diverse needs of patients and healthcare providers, thereby expanding their market presence and driving growth of the dry eye treatment devices market.
Advancements in technologies associated with intranasal tear neurostimulation devices
The emergence of the intranasal tear neurostimulator, recently FDA-approved for dry eye disease treatment, presents a notable opportunity in the dry eye treatment devices market. This innovative device is designed to stimulate mucosal nerves through minor electrical shocks, thereby increasing natural tear production via the nasolacrimal reflex pathway of the lacrimal function unit. This unit encompasses the lacrimal glands, ocular surface, and the sensory and motor nerves connecting these structures to maintain tear production and quality. This novel approach to DED treatment offers a promising opportunity for manufacturers and investors to tap into a growing market demand for effective, non-invasive solutions, thereby driving growth and innovation in the dry eye treatment sector.
The meibomian gland expression (MGX) segment held the largest share of 43% of the dry eye treatment devices market in 2023. Combining technologies such as intense pulsed light (IPL) with MGX has demonstrated notable improvements in dry eye symptoms and meibomian gland function, particularly in patients with refractory dry eye. MGX is a well-established technology in dermatology, widely utilized for treating various skin conditions, including telangiectasia, erythema, pigmentation, and aging skin, owing to its proven therapeutic efficacy.
For the treatment of meibomian gland dysfunction (MGD)-related dry eyes, MGX offers a convenient, safe, and effective solution. In cases where meibomian glands are severely blocked, traditional methods like hot compresses and lid massage may prove ineffective. Manual MGX, preferred by many specialists, clears blockages efficiently and at a lower cost compared to other interventions. This cost-effectiveness enables more frequent treatment repetitions, contributing to the growth of the dry eye treatment devices market by providing accessible and efficient solutions for patients suffering from MGD-related dry eye conditions.
The hospitals segment has held the largest revenue share of 49% in 2023, offering a diverse range of procedural therapies to tackle the condition comprehensively. These include punctual occlusion, low-level light therapy, meibomian gland thermal pulsation and expression, intense pulsed light therapy, and exfoliation. Recognition of long-term topical anti-inflammatory treatments like corticosteroids or cyclosporine for moderate to severe dry eye disease significantly evolved therapeutic approaches.
From traditional tear substitution to a more nuanced therapeutic algorithm, driven by advancements in pathophysiology understanding, diagnostic techniques, and novel therapies, the dry eye treatment devices market continues to expand. Ongoing research focusing on secretagogues, topical androgens, and new anti-inflammatory drugs promises further growth and innovation in dry eye treatment. The recent FDA approval of varenicline (Tyrvaya) administered via nasal spray adds to the treatment arsenal, highlighting a shift towards innovative delivery methods.
Segments Covered in the Report
By Technology
By End-use
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
